N-acetyl-aspartate (NAA) and myo-inositol (mI) are neurometabolites reflecting neuronal viability and astrocyte activity, respectively. These are quantified using proton magnetic resonance spectroscopy (1H-MRS) and may be biomarkers for Alzheimer's disease dementia (AD). Our objectives were: 1) Compare dorsolateral prefrontal cortex (DLPFC) NAA and mI levels between AD and cognitively healthy control participants (HC) 2) assess if NAA/mI ratio can distinguish groups, and 3) explore the relationship between metabolites and cognition. The study included 64 participants over 55, 41 with AD. Bilateral DLPFC NAA and mI levels were quantified using 3 T 1H-MRS and normalized to H2O. NAA and NAA/mI ratio were lower in AD vs. HC. mI was unchanged. The NAA/mI ratio at a cut-off value of 1.69 showed 59% sensitivity and 87% specificity at distinguishing AD from HC. NAA was associated positively with cognition. In conclusion, DLPFC metabolite changes suggest altered mitochondrial function in AD. NAA/mI ratio shows good specificity in distinguishing AD from HC, suggesting its role in complementing other biomarkers. Future studies should evaluate NAA/mI ratio with other disease specific biomarkers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cercor/bhae465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuronal viability/astrocyte activity ratio in the dorsolateral prefrontal cortex as a biomarker of Alzheimer's dementia: a proton magnetic resonance spectroscopy study.
Cereb Cortex
November 2024
Temerty Faculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, Ontario M5S 1A8, Canada.
N-acetyl-aspartate (NAA) and myo-inositol (mI) are neurometabolites reflecting neuronal viability and astrocyte activity, respectively. These are quantified using proton magnetic resonance spectroscopy (1H-MRS) and may be biomarkers for Alzheimer's disease dementia (AD). Our objectives were: 1) Compare dorsolateral prefrontal cortex (DLPFC) NAA and mI levels between AD and cognitively healthy control participants (HC) 2) assess if NAA/mI ratio can distinguish groups, and 3) explore the relationship between metabolites and cognition.
View Article and Find Full Text PDFMagnetic Resonance Spectroscopy (MRS) in Alzheimer's Disease.
Methods Mol Biol
March 2024
USC Mark and Mary Stevens Neuroimaging and Informatics Institute, USC, Los Angeles, CA, USA.
MRS is a noninvasive technique to measure different metabolites in the brain. Changes in the levels of certain metabolites can be used as surrogate markers for Alzheimer's disease. They can potentially be used for diagnosis, prediction of prognosis, or even assessing response to treatment.
View Article and Find Full Text PDFEffect of electroacupuncture at the acupoints for on cerebral metabolism in the patients with type 2 diabetes mellitus-associated cognitive dysfunction.
Zhongguo Zhen Jiu
December 2023
Changchun University of CM, Changchun 130117, Jilin Province.
Article Synopsis
- This study aimed to understand how cerebral metabolism is affected in patients with type 2 diabetes-related cognitive dysfunction (T2DACD) and to see how electroacupuncture (EA) might help improve their symptoms.
- The research involved 15 patients with T2DACD who received EA treatment at specific acupoints for eight sessions, while a control group of 22 healthy individuals was assessed before treatment.
- Various cognitive and metabolic tests were conducted, and the results showed notable differences in cognitive performance and metabolic markers between the two groups prior to EA treatment.
A comparative study of posterior cingulate metabolism in patients with mild cognitive impairment due to Parkinson's disease or Alzheimer's disease.
Sci Rep
August 2023
Department of Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Few comparative studies have assessed metabolic brain changes in cognitive impairment among neurodegenerative disorders, and the posterior cingulate cortex (PCC) is a metabolically active brain region with high involvement in multiple cognitive processes. Therefore, in this study, metabolic abnormalities of the PCC were compared in patients with mild cognitive impairment (MCI) due to Parkinson's disease (PD) or Alzheimer's disease (AD), as examined by proton magnetic resonance spectroscopy (H-MRS). Thirty-eight patients with idiopathic PD, including 20 with mild cognitive impairment (PDMCI) and 18 with normal cognitive function (PDN), 18 patients with probable mild cognitive impairment (ADMCI), and 25 healthy elderly controls (HCs) were recruited and underwent PCC H-MRS scans.
View Article and Find Full Text PDFMetabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models.
NMR Biomed
March 2023
Centre for Preclinical Imaging, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Changes in glioblastoma (GBM) metabolism was investigated in response to JAS239, a choline kinase inhibitor, using MRS. In addition to the inhibition of phosphocholine synthesis, we investigated changes in other key metabolic pathways associated with GBM progression and treatment response. Three syngeneic rodent models of GBM were used: F98 (N = 12) and 9L (N = 8) models in rats and GL261 (N = 10) in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!